ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO944

Relevance of Serum A Proliferation-Inducing Ligand (APRIL) as a Biomarker in South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort (GRACE-IgANI)

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Alexander, Suceena, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Mani, Selvin Sundar Raj, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Varughese, Santosh, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Barratt, Jonathan, University of Leicester, Leicester, United Kingdom
  • John, George, Christian Medical College Vellore, Vellore, Tamil Nadu, India

Group or Team Name


The role of serum APRIL as a biomarker in a prospective longitudinal South Asian IgAN cohort (GRACE-IgANI) and the impact of immunosuppression (IS) is not known.


Serum APRIL levels were measured in baseline and longitudinal sera (1year, 2year & 3year) in IgAN patients, and at baseline in disease controls and healthy controls by ELISA (R&D Systems; Catalog No: DY884B). Short course IS was given to patients with proteinuria ≥1g/day and/or renal impairment (73%). Composite outcome (CO) was defined as ≥50% fall in eGFR (CKD EPI) from baseline and/or eGFR <15ml/min/1.73m2 or RRT/death.


Lower baseline serum APRIL levels were diagnostic of IgAN in our cohort compared to disease controls and healthy controls (398 vs. 550 vs. 516 pg/mL, p=0.002). Serum APRIL levels had significant but weak positive correlation with baseline eGFR. MEST-C T1/T2 scores were significantly associated with lower baseline serum APRIL levels (T0: 490 vs. T1/T2: 372 pg/mL, p=0.007). In the treatment group I (low-risk group without IS), there was no significant association with CO at 3year. In the treatment group II (high-risk group with IS), there was significant association between lower serum APRIL levels at 1year, 2year, 3year and CO at 3year (1Y: 590 vs. 356 pg/mL, p<0.001; 2Y: 508 vs. 314 pg/mL, p=0.003; 3Y; 519 vs. 271, p<0.001) and the ROC curve of serum APRIL level at 1year showed good discrimination (AUC 0.75) for CO. There was a significant longitudinal increase in serum APRIL levels from baseline to 1year and which was sustained at 3year (Baseline: 414 vs. 1Y: 590 vs. 2Y: 508 vs. 3Y: 519 pg/mL, p<0.0001) in patients with favorable renal outcome.


Serum APRIL levels were an indepenpendent risk factor for progressive kidney disese in this cohort.


  • Government Support – Non-U.S.